The Vaccine Trials Group at the Telethon Institute for Child Health Research and Princess Margaret Hospital for Children is recruiting 150 adult volunteers to participate in the study.
Study leader, Dr Peter Richmond, said the Australian-developed vaccine has shown encouraging results in early trials.
"While there hasn't been any case of bird flu being spread from human to human, it's important that we're not complacent, and keep working to find ways to protect our community from a possible pandemic," Dr Richmond said.
"The best preparation is to have a vaccine available that is proven to be safe and effective - and that's our aim."
Dr Richmond said there was no live virus in the vaccine which meant there was no chance of catching the infection from the vaccination. He said the vaccine had already been shown to be safe in initial trials.
"What this study is most interested in determining is just how much of the vaccine is needed to provide good protection against bird flu," Dr Richmond said.
"In the initial trial a small dose of the vaccine generated a good immune response in about half of the participants.
"In this trial we will increase the dosage to see if that promotes good immunity in a larger proportion of participants, but even with the increase, the total amount of vaccine is still the same as what would be found in conventional flu vaccines."
If the vaccine is found to be safe and effective, stocks would then be manufactured to have on hand to protect against a possible bird flu pandemic.
Study volunteers will receive two doses of the vaccine, three weeks apart. They will then have blood tests over the following year to check their immunity.
Elizabeth Chester | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences